Skip to main content
Menu

Posts tagged with "Drug Development"

  • Biological News

    Fun With Epigenetics

    If you’ve been looking around the literature over the last couple of years, you’ll have seen an awful lot of excitement about epigenetic mechanisms. (Here’s a whole book on that very subject, for the hard core). Just do a Google search with “epigenetic” and “drug discovery” in it, any combination you like,… Read More
  • Drug Development

    Biogen: A “Decimated” Pipeline?

    You don’t want coverage like this: “Biogen CEO Tries to Refill Early-Stage Pipeline He Decimated”. That would be George Scanos: . . .Scangos and his research chief eliminated about 17 early-stage drug projects in 2010 and last year to hone the company’s focus, leaving it with only about four early-stage compounds. Biogen exi… Read More
  • Business and Markets

    Welcome To the Jungle! Here’s Your Panther.

    English has no word of its own for schadenfreude, so we’ve had to appropriate the German one, and we’re in the process of making it our own – just as we did with “kindergarten”, not to mention “ketchup” and “pyjamas”, among fifty zillion more. That’s because the emotion is not peculiar to… Read More
  • Drug Assays

    Do We Believe These Things, Or Not?

    Some of the discussions that come up here around clinical attrition rates and compound properties prompts me to see how much we can agree on. So, are these propositions controversial, or not? 1. Too many drugs fail in clinical trials. We are having a great deal of trouble going on with these failure rates, given… Read More
  • Chemical News

    Lead-Oriented Synthesis – What Might That Be?

    A new paper in Angewandte Chemie tries to open another front in relations between academic and drug industry chemists. It’s from several authors at GSK-Stevenage, and it proposes something they’re calling “Lead-Oriented Synthesis”. So what’s that? Well, the paper itself starts out as a quick tutorial on the state and p… Read More
  • Business and Markets

    More From Hua – A Change of Business Plans?

    You may remember the mention of Hua Pharmaceuticals here back in August, and the follow-up with details from the company. They’re trying to in-license drugs from other companies and get them approved as quickly as possible in China. The original C&E News article made them sound wildly ambitious, while the company’s own information… Read More
  • Aging and Lifespan

    The Sirtuin Saga

    Science has a long article detailing the problems that have developed over the last few years in the whole siturin story. That’s a process that I’ve been following here as well (scrolling through this category archive will give you the tale), but this is a different, more personality-driven take. The mess is big enough to… Read More
  • Drug Development

    Drugs, Airplanes, and Radios

    Wavefunction has a good post in response to this article, which speculates “If we designed airplanes the way we design drugs. . .” I think the original article is worth reading, but some – perhaps many – of its points are arguable. For example: Every drug that fails in a clinical trial or after it… Read More
  • Drug Assays

    Riding to the Rescue of Rhodanines

    There’s a new paper coming to the defense of rhodanines, a class of compound that has been described as “polluting the scientific literature”. Industrial drug discovery people tend to look down on them, but they show up a lot, for sure. This new paper starts off sounding like a call to arms for rhodanine fans… Read More
  • Cardiovascular Disease

    Pushing Onwards with CETP: The Big Money and the Big Risks

    Remember torcetrapib? Pfizer always will. The late Phase III failure of that CETP inhibitor wiped out their chances for an even bigger HDL-raising follow-up to LDL-lowering Lipitor, the world’s biggest drug, and changed the future of the company in ways that are still being played out. But CETP inhibition still makes sense, biochemically. And… Read More
...303132...